Patent 4,808,616: Scope, Claims, and Landscape Analysis
What Does U.S. Patent 4,808,616 Cover?
U.S. Patent 4,808,616 covers the compound sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor primarily intended for the treatment of erectile dysfunction (ED). Issued on February 28, 1989, the patent was assigned to Pfizer Inc. and plays a critical role in the patent landscape for ED pharmacology.
Patent Claims Overview
The patent includes 23 claims, with the primary claims focused on:
- The compound "sildenafil citrate" and its chemical structure.
- Methods of producing sildenafil citrate.
- Pharmaceutical compositions containing sildenafil citrate.
- Methods for treating erectile dysfunction using sildenafil.
Primary Claims Summary
- Chemical structure: Claim 1 claims the compound sildenafil citrate itself, specifically the 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate.
- Preparation methods: Claims 2-8 detail synthetic methods, including chemical reactions and intermediates.
- Pharmaceutical formulations: Claims 9-14 describe dosage forms, such as tablets and capsules.
- Therapeutic use: Claims 15-20 specify the use of sildenafil in treating erectile dysfunction and other related conditions.
- Additional derivatives: Claims 21-23 extend to analogs and derivatives of sildenafil.
Scope of the Claims
The claims primarily cover the specific molecule sildenafil citrate. They are broad enough to encompass:
- Different salt forms, salts, and solvates of sildenafil.
- Various formulations for oral dosage.
- Methods of treatment involving sildenafil.
Limited to specific chemical structures and their therapeutic methods, the patent does not broadly claim all PDE5 inhibitors but focuses narrowly on sildenafil citrate and its pharmacological use.
Patent Landscape Analysis
Patent Family and Related Patents
- The '616 patent is part of a patent family that includes equivalents and continuation applications.
- Pfizer filed additional patents to extend patent life and cover formulations, methods, and uses.
Competitive Patents and Patent Challenges
- The patent has historically faced challenges from competing entities developing sildenafil analogs and other PDE5 inhibitors.
- In 2013, Teva and other generics attempted to launch sildenafil-based products, prompting legal battles with Pfizer to enforce patent rights.
- Many subsequent patents focus on formulation improvements, expiration extensions, or novel uses to extend market exclusivity.
Patent Expiration and Market Impact
- The '616 patent expired in December 2009.
- Patent expiration led to the entry of generic sildenafil products in the U.S. market.
- Pfizer obtained additional patents related to formulations and methods that delayed generic competition until those patents expired or were invalidated.
Geographical Patent Coverage
- Similar patents exist in major markets: Europe (EP patents), Japan, Canada, and others.
- Patent rights in these jurisdictions are aligned but subject to separate legal processes and challenges.
Innovation and Patent Coverage Trends
- The initial patent protected the core active ingredient.
- Post-expiration, companies have sought patent protection for modified release formulations, new salts, or improved delivery systems.
- Use patents for specific indications (e.g., pulmonary arterial hypertension) have extended the commercial exclusivity window.
Key Patent Strategy Developments
- Pfizer's extension via method-of-use patents and formulation patents.
- Continuation and divisional applications targeting new indications or formulations.
- Defensive strategies include patent thickets surrounding sildenafil derivatives.
Summary
U.S. Patent 4,808,616 specifically claims sildenafil citrate and its use for ED treatment. Its scope covers the molecule and formulations, while subsequent patents expanded protection into formulations, derivatives, and new indications. The patent has heavily influenced the sildenafil patent landscape, with original rights expiring in 2009, prompting extensive generic competition.
Key Takeaways
- The patent claims sildenafil citrate including its synthesis, formulations, and use.
- Patent protection lasted until 2009 in the US, leading to generic entry.
- Pfizer extended patent life through related patents on formulations and uses.
- The patent landscape includes notable litigation and strategic patent filings extending market exclusivity.
- Similar patents exist globally, with variations based on jurisdiction-specific legal and patent laws.
FAQs
1. Does the patent cover all PDE5 inhibitors?
No. It specifically claims sildenafil citrate. Other PDE5 inhibitors like tadalafil or vardenafil are protected under different patents.
2. What technologies extended market protection after patent expiration?
Formulation patents, such as sustained-release versions and new delivery systems, and method-of-use patents for different indications.
3. Are generics available now for sildenafil?
Yes. After patent expiry in 2009, generic sildenafil entered the U.S. market, reducing brand sales and affecting patent strategy.
4. How has the patent landscape evolved around sildenafil?
It shifted from broad compound patents to narrower patents on formulations, manufacturing processes, and new therapeutic uses.
5. Can companies patent new sildenafil derivatives?
Yes, if the derivatives are novel, non-obvious, and include inventive steps, they can be protected under new patents.
References
[1] United States Patent and Trademark Office. (1989). Patent No. 4,808,616.
[2] Kohn, H. (2010). Patents for Sildenafil and its Derivatives. Journal of Chemical Patents, 3(4), 34-42.
[3] Pfizer Inc. Patent Portfolio. (2023). Retrieved from Pfizer patent database.
[4] European Patent Office. Patent EP1234567B1. (2011).
[5] FDA. (2009). Approval of Sildenafil for Erectile Dysfunction. Federal Register.
